All News

Jeffrey Bratberg, PharmD, FAPhA, a clinical professor for the college of pharmacy at the University of Rhode Island, discusses harm reduction and substance use disorder treatment.

Study results show significant differences in pCR rates, but the differences were not subtype-specific.

It is a means of supporting the growing provider status movement, which could enable clinical practice growth.

Expert discusses the updated guidelines for treating diabetes at the American Pharmacists Association (APhA) 2023 Meeting & Exposition in Phoenix, Arizona.

In the treatment of heart failure with reduced ejection fraction, combination therapy is the most effective in reducing all-cause death.

Improving patient safety and reducing harmful events is a team effort that includes both executive leadership and management as well as front line care teams.

As more drugs gain coverage, decision-makers will need to more accurately diagnose Alzheimer disease, especially in the community setting.

Students still have a myriad of career options, including at retail pharmacies, hospitals, and outside traditional practice.

Pharmacists are cited as one of the most stressed professions and a creative habit can help to improve focus, enhance productivity, and reduce stress.

Investigators analyze to see if there was an association of expected benefits and risk of vaccination.

Health benefits last for at least 5 years if shedding pounds occur via a lifestyle change program, the results of a research review show.

This drug is the first to control complement factor C5a, which is a protein that plays a significant but potentially harmful role in the body's immune response.

Data show that dose-response relationships and long-term safety of ICS in people with chronic obstructive pulmonary disease are unclear and require further investigation.

Implementing PrEP in retail community pharmacies increases patient accessibility but may be difficult to incorporate without modifying workflow.

Stephen Divers, MD, discussed the future of home infusion and drug development, and how both issues will be influential in the future of community pharmacy.

Improving the process of safe medication therapy management requires comfort, trust, and fostering a culture for safe communication.

Enfortumab vedotin-ejfv (Padcev, Astellas Pharma and Seagen Inc) with pembrolizumab (Keytruda, Merck) approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Additionally, study results show a clinically meaningful overall survival trend in the overall population among individuals with primary advanced or recurrent disease.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

For decades, pharmacy schools, residents, and fellows have been training to work alongside physicians, but that has not prepared us for what is coming.

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

A strong theme of recent conferences was the push for greater awareness of pharmacists' roles in patient advocacy and patient education.

Pharmacies need to differentiate themselves through faster and cheaper care, while delivering health outcomes across the patient journey.

This method has proven economically appealing, but further confirmation of these findings is needed, according to investigators.

Some common questions for oncology pharmacists are about concurrent use of complementary and alternative medicine supplements and natural products.

Thought-provoking economic, ethical conundrums accompany recent explosion in growth of glucagon-like peptide-1 products for medically assisted weight loss

Transplant patients must adhere to lifelong regimens and those caring for them must consider their regimen as the patients intersect with different parts of the health care system.

On March 1, 2023, Eli Lilly and Company said it would take steps to cap insulin prices, and Novo Nordisk and Sanofi followed suit 2 weeks later.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

Fomepizole, an FDA-approved drug to treat methanol poisoning, and erythromycin could offer a novel therapeutic option to fight drug-resistant S. pneumoniae.